Monoclonal Antibodies, Gene Silencing and Gene Editing (CRISPR) Therapies for the Treatment of Hyperlipidemia-The Future Is Here.
Melody HermelMadison LiebermanLeandro SlipczukJamal S RanaSalim S ViraniPublished in: Pharmaceutics (2023)
Hyperlipidemia is a significant risk factor for atherosclerotic cardiovascular disease. Undertreatment of elevated lipids persists despite existing therapies. Here, we provide an update on monoclonal antibodies, gene silencing therapies, and gene editing techniques for the management of hyperlipidemia. The current era of cutting-edge pharmaceuticals targeting low density lipoprotein cholesterol, PCSK9, lipoprotein (a), angiopoietin-like 3, and apolipoprotein C3 are reviewed. We outline what is known, studies in progress, and futuristic goals. This review of available and upcoming biotechnological lipid therapies is presented for clinicians managing patients with familial hyperlipidemia, statin intolerance, hypertriglyceridemia, or elevated lipoprotein (a) levels.
Keyphrases
- cardiovascular disease
- high fat diet
- low density lipoprotein
- crispr cas
- type diabetes
- high fat diet induced
- coronary artery disease
- adipose tissue
- genome editing
- fatty acid
- public health
- gene expression
- cancer therapy
- drug delivery
- cardiovascular events
- metabolic syndrome
- current status
- skeletal muscle
- cardiovascular risk factors
- replacement therapy